Stanford Grad, 21, Raises $11M for AI-Powered Hormone-Tracking Wearable
Key Takeaways
- ▸21-year-old Stanford grad Jenny Duan closed $11M seed round for Clair Health as she graduated, building AI-powered non-invasive hormone monitor for women
- ▸Wearable uses 10 proprietary biosensors including biomagnetic sensors to achieve 94% accuracy in detecting menstrual cycle phase, matching at-home test standards without blood draws or invasive procedures
- ▸Launching as wellness product in November 2026 with 25,000-person waitlist; pursuing FDA clearance for clinical use; targets femtech market projected to reach $97B by 2030
Summary
Jenny Duan, 21, closed an $11 million seed round for Clair Health just as she graduated from Stanford University with a degree in Symbolic Systems. The startup, co-founded with Abhinav Agarwal, is building the first continuous, non-invasive wearable hormone monitor for women, using proprietary AI and a stack of 10 biosensors—including biomagnetic sensors not found in competing consumer wearables—to infer a woman's position in her menstrual cycle.
Clair's wristband measures physiological signals including skin temperature, heart rate variability, and electrodermal activity, then runs these markers through AI models to determine hormonal status with 94% accuracy, matching the performance of at-home ovulation strips. Unlike blood tests or urine strips, which measure hormone metabolites rather than hormones directly, Clair's approach offers continuous monitoring. The company is entering the market as a wellness product in November 2026 and pursuing FDA clearance afterward—a faster path to revenue while building credibility for clinical use.
The global femtech market is projected to grow nearly threefold from $39 billion in 2024 to $97 billion by 2030. Though competitors like Whoop and Oura have launched women's health features, neither was built from the ground up for hormone monitoring. Clair already has a 25,000-person waitlist, sold out its presale, and received over 100 letters of intent from fertility clinics. The $11M seed round was led by Khosla Ventures and backed by a16z Speedrun, Brydge Club, Cartan Capital, and others.
Editorial Opinion
Clair Health's entry into femtech represents a timely shift toward women-centered health monitoring. By building sensors and AI specifically for hormone tracking rather than retrofitting existing hardware, the company addresses a genuine gap where women's health has been an afterthought in wearable technology. The combination of substantial seed funding, strong market validation (25K waitlist, 100+ clinic partnerships), and a visionary founder positions Clair to disrupt an industry long dominated by blood tests and urine strips. However, clinical validation will be the ultimate test—the promised Stanford studies and FDA pathway will determine whether this approach truly delivers on its promise.
